Works matching IS 11727047 AND DT 2021 AND VI 35 AND IP 9


Results: 8
    1
    2
    3
    4

    Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.

    Published in:
    CNS Drugs, 2021, v. 35, n. 9, p. 925, doi. 10.1007/s40263-021-00846-5
    By:
    • Ceban, Felicia;
    • Rosenblat, Joshua D.;
    • Kratiuk, Kevin;
    • Lee, Yena;
    • Rodrigues, Nelson B.;
    • Gill, Hartej;
    • Subramaniapillai, Mehala;
    • Nasri, Flora;
    • Lui, Leanna M. W.;
    • Lipsitz, Orly;
    • Kumar, Anil;
    • Lee, Jung Goo;
    • Chau, Edmond H.;
    • Cao, Bing;
    • Lin, Kangguang;
    • Ho, Roger C.;
    • Mansur, Rodrigo B.;
    • Swainson, Jennifer;
    • McIntyre, Roger S.
    Publication type:
    Article
    5
    6

    Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.

    Published in:
    CNS Drugs, 2021, v. 35, n. 9, p. 1009, doi. 10.1007/s40263-021-00840-x
    By:
    • Castelnovo, Giovanni;
    • Gerlach, Oliver;
    • Freedman, Mark S.;
    • Bergmann, Arnfin;
    • Sinay, Vladimiro;
    • Castillo-Triviño, Tamara;
    • Kong, George;
    • Koster, Thijs;
    • Williams, Heather;
    • Gafson, Arie R.;
    • Killestein, Joep
    Publication type:
    Article
    7
    8